Autoantibodies against contactin-associated protein 2 (Caspr2) are associated with a variety of clinical phenotypes including limbic encephalitis, neuromyotonia, cerebellar dysfunction, dysautonomia, insomnia, movement disorders, and neuropathic pain [1–4]. Here, CNTNAP2 is linked to insomnia measurement.